The Why Behind Our Work
We imagine a world where people living with genetic diseases can fully benefit from the promise of genetic medicines. Our novel mRNA and gene correction therapeutics have the potential to make this a reality.
Our Story Begins with Unconventional Thinking
For decades, LNP delivery was confined to the liver, limiting the reach of genetic medicines. Our co-founder, Dr. Daniel J. Siegwart, challenged that constraint by adding a fifth, distinct lipid to conventional LNPs, creating a way to direct them to specific organs and cells, bypassing the liver when needed. This breakthrough led to the development of SORT (Selective ORgan Targeting) LNPs, which power ReCode’s expanding pipeline of genetic medicines designed to reach the organs where they’re needed most.
We are pioneering disease-modifying mRNA and gene correction therapeutics for genetically defined diseases with few or no current treatment options.
Our lead programs are focused on primary ciliary dyskinesia and cystic fibrosis.
Therapeutic Areas of Focus
Cystic Fibrosis (CF)
Using the SORT LNP platform, we are tackling CF from multiple angles, including mRNA therapy and gene correction, to target the underlying cause of the disease so that more people with CF may benefit.
Primary Ciliary Dyskinesia (PCD)
ReCode is developing an mRNA-based therapy designed to restore ciliary function in the lungs of people with PCD caused by pathogenic mutations in the DNAI1 gene.
Future Indications
ReCode is expanding its pipeline to develop potential therapies for other rare and common genetic diseases including musculoskeletal, central nervous system, liver, and infectious disease indications.
